Umbilical Cord Mesenchymal Stem Cells is a promising therapy for Leukemia, GVHD, and Aplastic Anemia
Umbilical cord mesenchymal stem cells (UC-MSCs) are emerging as promising therapies for hematological diseases due to their high proliferation, low immunogenicity, and strong immunomodulatory properties. UC-MSCs support hematopoietic stem cell growth, reduce graft-versus-host disease (GVHD), and improve outcomes after stem cell transplantation. The therapy can potentially be applied in treating aplastic anemia, immune thrombocytopenia, and certain blood cancers. Their ability to regulate immune responses and target tumor cells makes them valuable in regenerative medicine and oncology.










